FindTrial
Sign In

Exploration into Dose - Effect Relationship of EX-HN6 blood letting in treatment of hordeolum

Exploration into Dose - Effect Relationship of EX-HN6 blood letting in treatment of hordeolum

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013518
Enrollment
Unknown
Registered
2017-11-24
Start date
2018-01-01
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hordeolum

Interventions

Western medicine group:Western medicine
EX-HN6 blood letting group1:EX-HN6 blood letting +Western medicine
EX-HN6 blood letting group2:EX-HN6 blood letting +Western medicine

Sponsors

Tianjin First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) meet the clinical diagnostic criteria of hordeolum; (2) patients diagnosed with early hordeolum: the onset time is 0.5-3 days; (3) hordeolum with no purulent; (4) the condition is mild and moderate; (5) Aged 6 ~ 65 years old; (6) volunteered to participate in this study, signed informed consent.

Exclusion criteria

Exclusion criteria: (1) those with low body resistance; (2) oral hormones, antibiotics and immunosuppressive agents; (3) coagulation disorders; (4) ear abscess disease; (5) drug allergy patients (levofloxacin hydrochloride eye drops, erythromycin eye ointment); (6) pregnant women.

Design outcomes

Primary

MeasureTime frame
Symptoms indicators;Signs;Efficient;—

Secondary

MeasureTime frame
safety;—

Countries

China

Contacts

Public ContactHongwei Qiao

Tianjin First Central Hospital

hongweity03@163.com+86 18622796140

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026